Source comparison
MOTS-c vs Other Mitochondrial Peptides: Research Comparison
When evaluating mitochondrial peptides for visceral fat reduction research, MOTS-c is often compared to other peptides targeting metabolic pathways. Here's how current research differentiates them: MOTS-c AMPK activation → fatty acid oxidation in adipocytes 27
This comparison does not assign a generated winner or score.
- When evaluating mitochondrial peptides for visceral fat reduction research, MOTS-c is often compared to other peptides targeting metabolic pathways. Here's how current research differentiates them:
- MOTS-c
- AMPK activation → fatty acid oxidation in adipocytes
- 27–31% reduction in visceral adipose tissue mass (8-week studies)
- 3–5x weekly
- Most direct evidence for visceral fat-specific reduction; limited human data but mechanistic rationale is strongest
- Humanin
- Anti-apoptotic signalling, insulin sensitisation
- Indirect via improved glucose metabolism; no direct lipolysis data
- Daily
- Supports metabolic health but lacks visceral fat specificity
- SS-31 (Elamipretide)
- Mitochondrial membrane stabilisation
- Improves mitochondrial function but minimal fat mass changes observed
- Cardioprotective focus; not primarily a metabolic intervention
- AOD-9604
- Growth hormone fragment targeting lipolysis
- Non-specific fat reduction; subcutaneous and visceral equally affected
- Mechanism overlaps with growth hormone pathways; less mitochondrial specificity
- MOTS-c stands out because its mechanism directly links mitochondrial function to visceral adipocyte metabolism. Humanin and SS-31 improve mitochondrial health broadly but don't preferentially target fat oxidation. AOD-9604 stimulates lipolysis through growth hormone pathways, which affects all adipose depots equally. Not the visceral-specific reduction seen with MOTS-c.